Table 2.
Demographic and clinical characteristics of patients
| CE interviews (n = 41) | CD interviews (n = 18) | |
|---|---|---|
| Gender, n (%) | ||
| Male | 2 (5) | 1 (6) |
| Female | 39 (95) | 17 (94) |
| Mean age, years (SD) | 47.7 (12.6) | 50.8 (14.4) |
| Ethnicity, n (%) | ||
| Caucasian | 22 (55) | 7 (39) |
| African American | 10 (25) | 11 (61) |
| Latino/Hispanic | 5 (12) | 0 |
| Other | 2 (5) | 0 |
| Asian | 1 (2) | 0 |
| Marital status, n (%) | ||
| Married | 16 (39) | 5 (28) |
| Lives with partner | 0 | 1 (6) |
| Widowed/divorced/separated | 8 (19) | 6 (33) |
| Single/never married | 17 (42) | 5 (28) |
| No response | 0 | 1 (6) |
| Employment, n (%) | ||
| Not currently working for pay | 11 (27) | 2 (11) |
| Working full time | 11 (27) | 4 (22) |
| Working part time | 1 (2) | 2 (11)a |
| Retired | 6 (15) | 5 (28) |
| Disabled | 0 | 5 (28) |
| Other | 12 (29) | 0 |
| Mean time since SLE diagnosis, years (SD)b | 8.56 (8.13), range < 1–35 (n = 38) | 11.28 (10.38), range 1–38 (n = 14) |
| Mean SELENA-SLEDAIc (SD) | 6.02 (3.60) (n = 37) | 6.06 (2.53) |
| Mean SLICC/ACR damage indexc (SD) | 5.96 (1.74) (n = 25) | 6.00 (1.83) (n = 10) |
| SLE severity, n (%) | ||
| Mild | 22 (54) | 9 (50) |
| Moderate | 18 (44) | 9 (50) |
| Severe | 1 (2) | 0 |
| Current SLE treatmentd, n (%) | ||
| Hydroxychloroquine | 29 (71) | 14 (78) |
| Corticosteroids | 19 (46) | 10 (56) |
| NSAIDs | 7 (17) | 2 (11) |
| Belimumab | 6 (15) | 2 (11) |
| Methotrexate | 4 (10) | 3 (17) |
| Concomitant conditione, n (%) | ||
| Fibromyalgia | 10 (24) | 4 (22) |
| Osteopenia/osteoporosis | 9 (22) | 5 (28) |
| Anxiety | 9 (22) | 3 (17) |
| Hypertension | 8 (20) | 4 (22) |
| Depression | 7 (17) | 2 (11) |
| Rheumatoid arthritis | 5 (12) | 1 (6) |
| Asthma | 4 (10) | 2 (11) |
| Osteoarthritis | 4 (10) | 4 (22) |
| Sjögren’s syndrome | 4 (10) | 2 (11) |
| Lupus nephritis | 3 (7) | 4 (22) |
| Hyperlipidemia/hypercholesterolemia | 2 (5) | 3 (17) |
| Vasculitis | 2 (5) | 2 (11) |
| Other renal diseases (non-lupus)/ESRD | 1 (2) | 2 (11) |
| Congestive heart failure | 0 | 2 (11) |
aOne patient was also a student; bif patients had moved practice since initial SLE diagnosis it was not always possible to precisely determine their date of diagnosis; cwhen data were available; dsome patients were receiving more than 1 treatment; ereported by ≥10% of patients
CE concept elicitation, CD cognitive debriefing, ESRD end stage renal disease, NSAIDs non-steroidal anti-inflammatories, SD standard deviation, SELENA-SLEDAI Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index, SLE systemic lupus erythematosus, SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of Rheumatology